{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:24:57Z","timestamp":1792290297375,"version":"4.4.0"},"reference-count":57,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,3,16]],"date-time":"2006-03-16T00:00:00Z","timestamp":1142467200000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Basic Clin Pharma Tox"],"published-print":{"date-parts":[[2006,3]]},"abstract":"<jats:p><jats:bold>Abstract:<\/jats:bold> Because endogenous hormones play a major role in the risk of breast, endometrial and ovarian cancer, the impact on risk of oral contraceptives and of hormonal therapy given at about the time of menopause has been a major concern. Numerous studies provide insight into whether risk is increased or decreased in association with use of these preparations. Oral contraceptives present a chemopreventive opportunity for endometrial cancer and ovarian cancer as risk is dramatically lower among women who have used these preparations than among those who have not. Balanced against this is the potential for risk of breast cancer to be increased with oral contraceptive use. A pooled analysis of studies conducted through the early 1990s found that only current or recent users were at higher risk of breast cancer, but two more recent studies provide conflicting results with one showing no impact of oral contraceptives on risk of any group of women and the other showing an increase in risk with use. Among women participating in observational studies who are current or recent users of oestrogen therapy and who have relatively long durations of use, risk of breast cancer is modestly elevated; results from the Women's Health Initiative trial, based on a relatively short duration of oestrogen use are consistent with these observations. Oestrogen therapy increases endometrial cancer risk dramatically. It may also increase the risk of ovarian cancer; however more study of this issue is needed as the literature is inconsistent. Combined oestrogen and progestin therapy increases breast cancer risk by as much as 10% per year of use. Endometrial cancer risk is not elevated when combined therapy is given in a cyclic manner with progestin administered only part of the time and it is reduced when both oestrogen and progestin are administered on a daily basis. As with oestrogen therapy, the impact of combined therapy on ovarian cancer risk is uncertain.<\/jats:p>","DOI":"10.1111\/j.1742-7843.2006.pto_277.x","type":"journal-article","created":{"date-parts":[[2006,3,16]],"date-time":"2006-03-16T15:30:37Z","timestamp":1142523037000},"page":"288-296","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["The Risk of Breast, Endometrial and Ovarian Cancer in Users of Hormonal Preparations"],"prefix":"10.1111","volume":"98","author":[{"given":"Leslie","family":"Bernstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,3,16]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.290.13.1739"},{"key":"e_1_2_6_3_1","first-page":"1","volume-title":"Cancer prevention","author":"Bernstein L.","year":"1990"},{"key":"e_1_2_6_4_1","first-page":"265","article-title":"Estrogen replacement therapy and endometrial cancer risk: unresolved issues","volume":"81","author":"Brinton L. A.","year":"1993","journal-title":"Obstet. Gynecol."},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(79)91435-1"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.249.12.1600"},{"key":"e_1_2_6_7_1","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1001\/jama.1983.03330360036032","article-title":"Oral contraceptive use and the risk of ovarian cancer","volume":"249","author":"Centers for Disease Control Cancer and Steroid Hormone Study","year":"1983","journal-title":"J. Amer. Med. Ass."},{"key":"e_1_2_6_8_1","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1001\/jama.1987.03390060086029","article-title":"Combination oral contraceptive use and the risk of endometrial cancer","volume":"257","author":"Centers for Disease Control Cancer and Steroid Hormone Study","year":"1987","journal-title":"J. Amer. Med. Ass."},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.24.3243"},{"key":"e_1_2_6_10_1","first-page":"1713","article-title":"Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53,297 women with breast cancer and 100,239 women without breast cancer from 54 epidemiological studies","volume":"147","author":"Collaborative Group on Hormonal Factors in Breast Cancer","year":"1996","journal-title":"Lancet"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)08233-0"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(99)00179-1"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.20.2253"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1086\/340778"},{"key":"e_1_2_6_15_1","first-page":"1058","volume-title":"Cancer epidemiology and prevention","author":"Grady D.","year":"1996"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0029-7844(94)00383-O"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.AOG.0000154152.12088.48"},{"key":"e_1_2_6_18_1","first-page":"708","article-title":"A quantitative assessment of oral contraceptive use and risk of ovarian cancer","volume":"80","author":"Hankinson S. E.","year":"1992","journal-title":"Obstet. Gynecol."},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.78.11.1479"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1983.127"},{"key":"e_1_2_6_21_1","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1001\/jama.1982.03320290021022","article-title":"Protection against endometrial carcinoma by combination\u2010product oral contraceptives","volume":"247","author":"Hulka B. S.","year":"1982","journal-title":"J. Amer. Med. Ass."},{"key":"e_1_2_6_22_1","volume-title":"National Prescription Audit","author":"IMS, America","year":"1987"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198010303031807"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113417"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1988.44"},{"key":"e_1_2_6_26_1","first-page":"1374","article-title":"Use of oral contraceptives and breast cancer risk: The Norwegian\u2010Swedish Women's Lifestyle and Health Cohort Study","volume":"11","author":"Kumle M.","year":"2002","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.3.334"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602617"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.0.CO;2-6"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa013202"},{"key":"e_1_2_6_31_1","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/S0140-6736(03)14065-2","article-title":"Breast cancer and hormone\u2010replacement therapy in the Million Women Study","volume":"362","author":"Million Women Study Collaborators","year":"2003","journal-title":"Lancet"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66455-0"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/152.3.233"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023066304473"},{"key":"e_1_2_6_35_1","first-page":"292","volume-title":"Current therapy in oncology","author":"Pike M. C.","year":"1993"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(83)90450-6"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2004.03.013"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207899"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/16.2.215"},{"key":"e_1_2_6_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwf048"},{"key":"e_1_2_6_41_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.285.11.1460"},{"key":"e_1_2_6_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1071-5576(98)00017-3"},{"key":"e_1_2_6_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910490612"},{"key":"e_1_2_6_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/92.4.328"},{"key":"e_1_2_6_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.4.485"},{"key":"e_1_2_6_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/94.1.32"},{"key":"e_1_2_6_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/12.9.1851"},{"key":"e_1_2_6_48_1","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.2002.6746"},{"key":"e_1_2_6_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9378(75)90509-8"},{"key":"e_1_2_6_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(85)90524-0"},{"key":"e_1_2_6_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910540214"},{"key":"e_1_2_6_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.14.1701"},{"key":"e_1_2_6_53_1","first-page":"973","article-title":"Oral contraceptive use and breast cancer risk in young women","volume":"1","author":"UK National Case\u2010Control Study Group","year":"1989","journal-title":"Lancet"},{"key":"e_1_2_6_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01830241"},{"key":"e_1_2_6_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198003063021004"},{"key":"e_1_2_6_56_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a116427"},{"key":"e_1_2_6_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/17.2.263"},{"key":"e_1_2_6_58_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1704"}],"container-title":["Basic &amp; Clinical Pharmacology &amp; Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-7843.2006.pto_277.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1742-7843.2006.pto_277.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T20:45:56Z","timestamp":1696970756000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-7843.2006.pto_277.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,3]]}},"alternative-id":["10.1111\/j.1742-7843.2006.pto_277.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1742-7843.2006.pto_277.x","archive":["Portico"],"relation":{},"ISSN":["1742-7835","1742-7843"],"issn-type":[{"value":"1742-7835","type":"print"},{"value":"1742-7843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3]]},"assertion":[{"value":"2006-03-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}